Commercial anti-CD19 CAR T cell therapy fo patients with relapsed/refractory aggressive B cell lymphoma in a European center.

https://pubmed.ncbi.nlm.nih.gov/32744738/

Authors: Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A et al.

Am J Hematol 2020;95(11):1324-1333.